ABEO
Price
$6.16
Change
-$0.08 (-1.28%)
Updated
Jun 13 closing price
Capitalization
315.13M
65 days until earnings call
CAPR
Price
$11.78
Change
-$2.16 (-15.49%)
Updated
Jun 13 closing price
Capitalization
538.44M
54 days until earnings call
Interact to see
Advertisement

ABEO vs CAPR

Header iconABEO vs CAPR Comparison
Open Charts ABEO vs CAPRBanner chart's image
Abeona Therapeutics
Price$6.16
Change-$0.08 (-1.28%)
Volume$373.89K
Capitalization315.13M
Capricor Therapeutics
Price$11.78
Change-$2.16 (-15.49%)
Volume$3.12M
Capitalization538.44M
ABEO vs CAPR Comparison Chart
Loading...
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CAPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABEO vs. CAPR commentary
Jun 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABEO is a Hold and CAPR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 14, 2025
Stock price -- (ABEO: $6.16 vs. CAPR: $11.78)
Brand notoriety: ABEO and CAPR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABEO: 18% vs. CAPR: 132%
Market capitalization -- ABEO: $315.13M vs. CAPR: $538.44M
ABEO [@Biotechnology] is valued at $315.13M. CAPR’s [@Biotechnology] market capitalization is $538.44M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.9B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABEO’s FA Score shows that 0 FA rating(s) are green whileCAPR’s FA Score has 0 green FA rating(s).

  • ABEO’s FA Score: 0 green, 5 red.
  • CAPR’s FA Score: 0 green, 5 red.
According to our system of comparison, ABEO is a better buy in the long-term than CAPR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABEO’s TA Score shows that 3 TA indicator(s) are bullish while CAPR’s TA Score has 6 bullish TA indicator(s).

  • ABEO’s TA Score: 3 bullish, 4 bearish.
  • CAPR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, CAPR is a better buy in the short-term than ABEO.

Price Growth

ABEO (@Biotechnology) experienced а -8.61% price change this week, while CAPR (@Biotechnology) price change was -17.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.75%. For the same industry, the average monthly price growth was +12.94%, and the average quarterly price growth was +4.02%.

Reported Earning Dates

ABEO is expected to report earnings on Aug 18, 2025.

CAPR is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (-0.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CAPR($538M) has a higher market cap than ABEO($315M). ABEO YTD gains are higher at: 10.592 vs. CAPR (-14.638). CAPR has higher annual earnings (EBITDA): -34.79M vs. ABEO (-64.95M). ABEO has more cash in the bank: 110M vs. CAPR (85M). CAPR has less debt than ABEO: CAPR (1.65M) vs ABEO (23.1M). CAPR has higher revenues than ABEO: CAPR (23.2M) vs ABEO (0).
ABEOCAPRABEO / CAPR
Capitalization315M538M59%
EBITDA-64.95M-34.79M187%
Gain YTD10.592-14.638-72%
P/E RatioN/AN/A-
Revenue023.2M-
Total Cash110M85M129%
Total Debt23.1M1.65M1,401%
FUNDAMENTALS RATINGS
ABEO vs CAPR: Fundamental Ratings
ABEO
CAPR
OUTLOOK RATING
1..100
2219
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
10067
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
4335
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABEO's Valuation (61) in the Pharmaceuticals Generic industry is in the same range as CAPR (76) in the Biotechnology industry. This means that ABEO’s stock grew similarly to CAPR’s over the last 12 months.

CAPR's Profit vs Risk Rating (67) in the Biotechnology industry is somewhat better than the same rating for ABEO (100) in the Pharmaceuticals Generic industry. This means that CAPR’s stock grew somewhat faster than ABEO’s over the last 12 months.

CAPR's SMR Rating (95) in the Biotechnology industry is in the same range as ABEO (97) in the Pharmaceuticals Generic industry. This means that CAPR’s stock grew similarly to ABEO’s over the last 12 months.

CAPR's Price Growth Rating (35) in the Biotechnology industry is in the same range as ABEO (43) in the Pharmaceuticals Generic industry. This means that CAPR’s stock grew similarly to ABEO’s over the last 12 months.

CAPR's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ABEO (100) in the Pharmaceuticals Generic industry. This means that CAPR’s stock grew similarly to ABEO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABEOCAPR
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 9 days ago
83%
Bullish Trend 9 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 16 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 2 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CAPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PIREX28.99N/A
N/A
Principal Real Estate Securities Inst
VNSYX22.44N/A
N/A
Natixis Vaughan Nelson Select Y
TRXIX12.24N/A
N/A
Catalyst/MAP Global Balanced I
BMISX7.08N/A
N/A
BNY Mellon Income Stock C
BMSVX14.45N/A
N/A
MFS Blended Research Mid Cap Eq R4

ABEO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABEO has been loosely correlated with ERAS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ABEO jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABEO
1D Price
Change %
ABEO100%
-1.36%
ERAS - ABEO
47%
Loosely correlated
-3.27%
ZYME - ABEO
45%
Loosely correlated
-3.28%
CRNX - ABEO
45%
Loosely correlated
-1.24%
APGE - ABEO
45%
Loosely correlated
+6.26%
DAWN - ABEO
44%
Loosely correlated
-0.30%
More

CAPR and

Correlation & Price change

A.I.dvisor tells us that CAPR and SNDX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CAPR and SNDX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CAPR
1D Price
Change %
CAPR100%
-15.49%
SNDX - CAPR
32%
Poorly correlated
-3.94%
WVE - CAPR
32%
Poorly correlated
-3.47%
SRPT - CAPR
31%
Poorly correlated
-3.03%
ABEO - CAPR
31%
Poorly correlated
-1.36%
MDGL - CAPR
30%
Poorly correlated
-0.55%
More